论文部分内容阅读
目的:为了观察马蔺子素配合放射治疗食管癌的增敏疗效及其毒副反应.方法:从1996年6月至1997年6月采用马蔺子素配合放疗治疗食管癌患者36例(增敏组)与单纯放疗组36例(对照组),进行临床观察.结果:肿瘤消退率在增敏组为 72.2%(26/36),对照组为 52.8%(19/36),两组间差异显著(tP<0.05);肿瘤消失时照射总剂量,在增敏组为 56.2Gy,对照组为64.2 Gy,增敏比为1.13.临床症状改善,进食梗阻改善率,增敏组为75%(27/36),对照组为54%(20/36),胸背疼痛消失两组无明显差异;外周白细胞低于4×10~9/L者,增敏组为22%(8/36),对照组为42%(15/36);患者1年和2年生存率,增敏组为75%(27/36)和58%(21/36),对照组为61%(22/36)和42%(15/36).结论:实验研究表明马蔺子素与放疗合用治疗食管癌可提高肿瘤消退率和近期生存率,有显著的放疗增敏作用,对患者无特殊毒副作用,可能是目前较为理想的放射增敏剂.
OBJECTIVE: To observe the sensitization efficacy and toxic and side effects of madoxazin combined with radiation therapy for esophageal cancer. METHODS: From June 1996 to June 1997, 36 cases of esophageal cancer patients (sensitized group) were treated with madoxin and radiotherapy. Thirty-six patients (control group) in the radiotherapy alone group underwent clinical observation. Results: The tumor extinction rate was 72.2% (26/36) in the sensitization group and 52.8% (19/36) in the control group. The difference was significant between the two groups. tP<0.05); The total dose of radiation when the tumor disappeared was 56.2Gy in the sensitized group, 64.2 Gy in the control group, and the sensitization ratio was 1.13. The improvement in clinical symptoms and eating obstruction was 75% in the sensitized group (27/ 36) In the control group, 54% (20/36) had no significant difference in the disappearance of thoracodorsal pain; peripheral white blood cells were lower than 4×10-9/L, and sensitization group was 22% (8/36). The group was 42% (15/36); the 1-year and 2-year survival rates were 75% (27/36) and 58% (21/36) in the sensitized group and 61% (22/36) in the control group. 42% (15/36). Conclusions: Experimental studies have shown that the treatment of esophageal cancer with melittin combined with radiotherapy can improve the tumor regression rate and recent survival rate. It has significant radiosensitization and no specific toxic side effects to the patient. It may be currently relatively Ideal radiosensitizer.